Tiny study probes GIP's role in gut blood flow for diabetes

NCT ID NCT06426823

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how the hormone GIP changes blood flow in the gut after a sugary drink in 10 people with type 2 diabetes. Researchers used a GIP-blocking drug to see what happens when GIP is stopped. The goal was to better understand GIP's role in digestion and metabolism, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GIP(3-30)NH2 (a GIP receptor blocker) and saline placebo
What this could lead to
If successful, this could clarify how GIP influences digestion and metabolism in type 2 diabetes, potentially guiding future treatments.
What could go wrong
This is a very small, completed study (10 people) focused on understanding basic mechanisms, not testing a treatment. Results may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLOOD FLOW are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rigshospitalet

    Copenhagen, 2200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.